These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 14613451)
1. Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan. Stacy J; Shaw E; Arledge MD; Howell-Smith D J Manag Care Pharm; 2003; 9(4):327-34. PubMed ID: 14613451 [TBL] [Abstract][Full Text] [Related]
2. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s). Cox ER; Motheral B; Mager D Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755 [TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Chancellor JV; Hunsche E; de Cruz E; Sarasin FP Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106 [TBL] [Abstract][Full Text] [Related]
4. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227 [TBL] [Abstract][Full Text] [Related]
5. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease. Joshua FF; Oakley SP; Major GA Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694 [TBL] [Abstract][Full Text] [Related]
6. Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study. Knijff-Dutmer EA; Postma MJ; van der Palen J; Brouwers JR; van de Laar MA Clin Ther; 2004 Jul; 26(7):1160-7. PubMed ID: 15336481 [TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490 [TBL] [Abstract][Full Text] [Related]
8. Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program. Gleason PP; Williams C; Hrdy S; Hartwig SC; Lassen D Pharmacotherapy; 2005 Jul; 25(7):924-34. PubMed ID: 16006271 [TBL] [Abstract][Full Text] [Related]
9. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Dai C; Stafford RS; Alexander GC Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363 [TBL] [Abstract][Full Text] [Related]
10. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790 [TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Kamath CC; Kremers HM; Vanness DJ; O'Fallon WM; Cabanela RL; Gabriel SE Value Health; 2003; 6(2):144-57. PubMed ID: 12641865 [TBL] [Abstract][Full Text] [Related]
12. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program. Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216 [TBL] [Abstract][Full Text] [Related]
13. Cost-effective use of NSAIDs: issues pertinent to coxib use in managed care. Fendrick AM Am J Manag Care; 2002 Nov; 8(17 Suppl):S529-41. PubMed ID: 12458822 [TBL] [Abstract][Full Text] [Related]
14. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. El-Serag HB; Graham DY; Richardson P; Inadomi JM Arch Intern Med; 2002 Oct; 162(18):2105-10. PubMed ID: 12374519 [TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470 [TBL] [Abstract][Full Text] [Related]
16. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. You JH; Lee KK; Chan TY; Lau WH; Chan FK Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942 [TBL] [Abstract][Full Text] [Related]
17. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672 [TBL] [Abstract][Full Text] [Related]
18. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel A; Krahn M; Naglie G Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781 [TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Spiegel BM; Targownik L; Dulai GS; Gralnek IM Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. Yun HR; Bae SC Rheumatol Int; 2005 Jan; 25(1):9-14. PubMed ID: 13680139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]